Affiliation:
1. Antibody and Vaccine Group, Cancer Sciences Unit, University of Southampton, Faculty of Medicine, General Hospital, Southampton, United Kingdom
Abstract
Abstract
Monoclonal antibody (mAb) therapeutics are revolutionizing cancer treatment; however, not all tumors respond, and agent optimization is essential to improve outcome. It has become clear over recent years that isotype choice is vital to therapeutic success with agents that work through different mechanisms, direct tumor targeting, agonistic receptor engagement, or receptor-ligand blockade, having contrasting requirements. Here we summarize how isotype dictates mAb activity and discuss ways in which this information can be used for the development of enhanced therapeutics.
Publisher
American Society of Hematology
Subject
Cell Biology,Hematology,Immunology,Biochemistry
Reference76 articles.
1. Antibody therapeutics in cancer.;Sliwkowski;Science,2013
2. Immune Checkpoint Blockade in Cancer Therapy.;Postow;J Clin Oncol,2015
3. IgG2a monoclonal antibodies inhibit human tumor growth through interaction with effector cells.;Herlyn;Proc Natl Acad Sci USA,1982
4. Therapy with monoclonal antibodies. II. The contribution of Fc gamma receptor binding and the influence of C(H)1 and C(H)3 domains on in vivo effector function.;Isaacs;J Immunol,1998
5. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets.;Clynes;Nat Med,2000
Cited by
88 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献